• SPX
  • $5,961.13
  • 0.21 %
  • $12.42
  • DJI
  • $44,305.48
  • 0.99 %
  • $435.12
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $18,975.62
  • 0.02 %
  • $3.20
SpringWorks Therapeutics, Inc. (SWTX) Stock Price, News & Analysis

SpringWorks Therapeutics, Inc. (SWTX) Stock Price, News & Analysis

Currency in USD Disclaimer

$38.68

$2.38

(6.54%)

Day's range
$36.24
Day's range
$39.61
50-day range
$28.21
Day's range
$39.61
  • Country: US
  • ISIN: US85205L1070
52 wk range
$20.19
Day's range
$53.92


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 18.10
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (SWTX)
  • Company SpringWorks Therapeutics, Inc.
  • Price $38.68
  • Changes Percentage (6.54%)
  • Change $2.38
  • Day Low $36.24
  • Day High $39.61
  • Year High $53.92

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $76.00
  • High Stock Price Target $76.00
  • Low Stock Price Target $50.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$5.15
  • Trailing P/E Ratio -7.81
  • Forward P/E Ratio -7.81
  • P/E Growth -7.81
  • Net Income $-325,104,000

Income Statement

Quarterly

Annual

Latest News of SWTX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

SpringWorks Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of SWTX in the last quarter?

    In the last quarter SpringWorks Therapeutics, Inc. earnings were on Tuesday, November, 12th. The SpringWorks Therapeutics, Inc. maker reported -$0.72 EPS for the quarter, beating analysts' consensus estimates of -$0.76 by $0.04.

  • What is the SpringWorks Therapeutics, Inc. stock price today?

    Today's price of SpringWorks Therapeutics, Inc. is $38.68 — it has increased by +6.54% in the past 24 hours. Watch SpringWorks Therapeutics, Inc. stock price performance more closely on the chart.

  • Does SpringWorks Therapeutics, Inc. release reports?

    Yes, you can track SpringWorks Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the SpringWorks Therapeutics, Inc. stock forecast?

    Watch the SpringWorks Therapeutics, Inc. chart and read a more detailed SpringWorks Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is SpringWorks Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by SpringWorks Therapeutics, Inc. stock ticker.

  • How to buy SpringWorks Therapeutics, Inc. stocks?

    Like other stocks, SWTX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is SpringWorks Therapeutics, Inc.'s EBITDA?

    SpringWorks Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in SpringWorks Therapeutics, Inc.’s financial statements.

  • What is the SpringWorks Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -59.6849642005, which equates to approximately -5,968.50%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in SpringWorks Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including SpringWorks Therapeutics, Inc.'s financials relevant news, and technical analysis. SpringWorks Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for SpringWorks Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review SpringWorks Therapeutics, Inc.’s technical analysis.

  • A revenue figure for SpringWorks Therapeutics, Inc. for its last quarter?

    SpringWorks Therapeutics, Inc. published it's last quarterly revenues at $49.30 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.